Newly Diagnosed Multiple Myeloma: The MASTER and GMMG-HD7 Trials
A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.
EP: 1.Emory Experts Discuss Multi-Agent Induction Regimens for Transplant-Eligible Newly Diagnosed Myeloma
Now Viewing
EP: 2.Newly Diagnosed Multiple Myeloma: The MASTER and GMMG-HD7 Trials
EP: 3.Treatment Approaches for Patients with Newly Diagnosed Multiple Myeloma
EP: 4.Maintenance Therapy Strategies for Transplant Eligible Multiple Myeloma
EP: 5.Case Presentation: An 82-Year-Old Woman with Transplant-Ineligible Multiple Myeloma
EP: 6.Transplant-Ineligible Multiple Myeloma: The MAIA Trial
EP: 7.Defining High-Risk Multiple Myeloma
EP: 8.Transplant-Ineligible Multiple Myeloma: The SWOG0777 Study
EP: 9.Blood-Based MRD Testing and Transplant-Ineligible Multiple Myeloma
EP: 10.Case Presentation: A 74-Year-Old Woman with Relapsed/Refractory Multiple Myeloma
EP: 11.Novel Therapies in Multiple Myeloma
EP: 12.Unmet Needs and the Future of Multiple Myeloma
EP: 13.Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
Recent Videos
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Related Content
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
